Hyperthermic Intraperitoneal Chemotherapy with Cisplatin After Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Inclusion Criteria

• Ability to understand and willingness to sign a written consent form. Ability to speak English
• Age > 18 years old
• Newly diagnosed stage III or IV epithelial (serous, mucinous, or endometrioid) ovarian, fallopian tube or peritoneal cancer diagnosed by: * Biopsy/histology (either by interventional radiology or laparoscopy) OR * Cytology; If diagnosis is based on cytology the following criteria must be met: ** Immunohistochemistry on the block from cytology to demonstrate Mullerian origin ** Presence of pelvic mass AND CA 125 > 200kU/I AND CA125/CEA ratio >= 25 ** Omental cake or other metastases larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size (diagnosed by computed tomography [CT]/magnetic resonance imaging [MRI], ultrasound, or laparoscopy)
• Patient planned for or currently receiving neoadjuvant chemotherapy due to the fact that optimal primary CRS was determined not to be feasible by the primary surgeon
• Patient must be planned or scheduled to undergo interval cytoreductive surgery after cycle 3 to 4 cycles of neoadjuvant chemotherapy
• Completion of 3-4 cycles of neoadjuvant chemotherapy (NACT) with standard therapy (carboplatin [area under the curve (AUC) 5-6] day [D]1 + paclitaxel [175 mg/m^2] D1 every 3 weeks) * Partial or complete response following 3-4 cycles based on clinician assessment
• Fit for major surgery, American Society of Anesthesiologists (ASA) 1 or ASA 2
• Eastern Cooperative Oncology Group (ECOG) performance-status score of 0-2
• Serum creatinine < 1.4 mg/dL * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• Creatinine clearance > 50 ml/min (estimated glomerular filtration rate [GFR], Cockcroft-Gault can be used) * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• White blood cell count > 3.5 K/cm * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• Absolute neutrophil count > 1.5 K/cm * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• Platelets > 100,000/ul * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• Total bilirubin within 1.5 x institutional upper limit of normal * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal * Note: Patients may be randomized prior to getting these labs, but must meet these lab criteria to be eligible to receive study interventions on the day of surgery with either HIPEC or cisplatin on the day prior to surgery

Exclusion Criteria

• Previous malignancy within 3 years prior to inclusion, with the exception of any prior malignancy unlikely to interfere with the outcomes of this study, and radically excised basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• Low grade serious carcinoma of the ovary or borderline ovarian tumors
• History or current diagnosis of inflammatory bowel disease
• History of severe allergic reactions to compounds of similar chemical or biologic composition to cisplatin, carboplatin, and paclitaxel that cannot be safely mitigated with desensitization protocols
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
• Patients in whom an optimal or complete cytoreduction cannot be performed will be excluded from HIPEC at the time of surgery and be replaced